News-Medical.Net (AZoM.com Pty.Ltd.) Drug Trial News Updateþ

[Guest guest]

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL

Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent

drugs that treat diseases through protein silencing, presented results of

preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181

and AVL-192. These inhibitors, due to their unique mechanism of action with

superior selectivity and potency, have potential as best-in-class, pan-genotype

HCV therapeutics.

http://www.news-medical.net/news/20100416/Preclinical-results-of-Avila-Therapeut\

ics-AVL-181-and-AVL-192-presented-at-EASL-Annual-Meeting.aspx

Jennerex presents positive interim data from Phase 2 clinical trial of JX-594

for HCC at 45th EASL

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced

the presentation of positive interim data from its randomized Phase 2 clinical

trial using JX-594 for the treatment of advanced hepatocellular carcinoma (HCC),

or liver cancer, at the 45th Annual Meeting of the European Association for the

Study of the Liver (EASL) in Vienna, Austria.

http://www.news-medical.net/news/20100419/Jennerex-presents-positive-interim-dat\

a-from-Phase-2-clinical-trial-of-JX-594-for-HCC-at-45th-EASL.aspx

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain

undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients

receiving ANA598 400 mg twice daily (bid) plus standard of care achieved

undetectable levels of virus at week eight in an ongoing Phase II study,

compared to 38% of patients receiving placebo plus SOC.

http://www.news-medical.net/news/20100419/Phase-II-study-Hepatitis-C-patients-re\

ceiving-ANA598-bid-plus-SOC-attain-undetectable-levels-of-virus.aspx

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can

be cured in 24 weeks

24 weeks of treatment could be sufficient to cure between 93 and 100% of

treatment-na-ve chronic hepatitis C virus (HCV) genotype 1 (G1) infected

patients if they have a fast antiviral response to Telaprevir (TVR) with

Peginterferon (PEG-IFN) and Ribavirin (RBV), according to new research presented

today at the International Liver Congress 2010, the Annual Meeting of the

European Association for the Study of the Liver in Vienna, Austria.

http://www.news-medical.net/news/20100417/G1-HCV-patients-having-fast-antiviral-\

response-to-TVR-with-PEG-IFN-and-RBV-can-be-cured-in-24-weeks.aspx

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV

patients at 45th EASL

InterMune, Inc. today announced results of all three cohorts from a 15-day Phase

1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as

RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically

infected with hepatitis C virus (HCV) genotype-1.

http://www.news-medical.net/news/20100416/InterMune-reports-Phase-1b-MAD-study-r\

esults-of-RTV-boosted-danoprevir-in-HCV-patients-at-45th-EASL.aspx

Findings strengthen promise of SCYNEXIS' SCY-635 for HCV treatment

Drug discovery company SCYNEXIS, Inc. today presented data supporting an

impressive resistance profile for SCY-635—a novel, oral cyclophilin inhibitor

being studied for the treatment of hepatitis C virus (HCV) infection. In the

study, SCYNEXIS demonstrated that the hepatitis C virus required multiple

mutations across two separate proteins in order to establish resistance to

SCY-635. The majority of HCV drugs on the market and in development require only

one targeted viral mutation to establish resistance.

http://www.news-medical.net/news/20100416/Findings-strengthen-promise-of-SCYNEXI\

S-SCY-635-for-HCV-treatment.aspx

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of

IDX320 for HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the

discovery and development of drugs for the treatment of human viral diseases,

today reported promising in vitro data for IDX320, an HCV protease inhibitor,

demonstrating potent and selective antiviral activity in multiple genotypes, or

strains, of the virus.

http://www.news-medical.net/news/20100416/Promising-pharmacokinetic-data-from-Id\

enix-Pharmaceuticals-Phase-I-study-of-IDX320-for-HCV.aspx

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9

agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a

Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in

null responder patients with chronic hepatitis C virus (HCV) infection were

presented at the 45th Annual Meeting of the European Association for the Study

of the Liver (EASL).

http://www.news-medical.net/news/20100416/Positive-interim-data-from-Idera-Pharm\

aceuticals-Phase-1-trial-of-IMO-2125-TLR9-agonist-presented-at-45th-EASL.aspx

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL

Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a

phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype

1 chronic hepatitis C. Study results were presented as a late breaking

communication at the International Liver Congress™ 2010, the 45th Annual Meeting

of the European Association for the Study of the Liver in Vienna, Austria.

http://www.news-medical.net/news/20100416/Results-from-Romark-Laboratories-STEAL\

TH-C-3-clinical-trial-presented-at-EASL-Annual-Meeting.aspx

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the

European Association for the Study of the Liver in Vienna, Vertex

Pharmaceuticals Incorporated today announced results from a Phase 1b clinical

trial of the investigational oral hepatitis C virus polymerase inhibitor,

VX-222. In the trial, treatment with VX-222 for three days was well-tolerated,

with all adverse events being mild to moderate in severity.

http://www.news-medical.net/news/20100416/Vertex-Pharmaceuticals-announces-resul\

ts-from-Phase-1b-clinical-trial-of-VX-222.aspx

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be

presented at EASL meeting

Achillion Pharmaceuticals, Inc. today presented data from the Company's ongoing

Phase 1 clinical trial of ACH-1625 to treat hepatitis C at the European

Association for the Study of the Liver's International Liver Congress taking

place at the Messe Wien Congress Center in Vienna, Austria from April

14-18, 2010.

http://www.news-medical.net/news/20100415/Phase-1-clinical-trial-results-of-Achi\

llion-Pharmaceuticals-ACH-1625-to-be-presented-at-EASL-meeting.aspx

Interim results from Pharmasset's phase 2a combination study of PSI-7977 with

Pegasys and Copegus for HCV

Pharmasset, Inc. announced today interim efficacy and safety results from its

ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with

Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in patients with

hepatitis C virus (HCV) genotype 1 who have not been treated previously.

http://www.news-medical.net/news/20100415/Interim-results-from-Pharmassets-phase\

-2a-combination-study-of-PSI-7977-with-Pegasys-and-Copegus-for-HCV.aspx

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the

discovery and development of drugs for the treatment of human viral diseases,

today announced interim data from a 14-day, phase IIa clinical trial evaluating

IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine

monophosphate, in HCV-infected patients.

http://www.news-medical.net/news/20100415/Interim-data-from-phase-IIa-clinical-t\

rial-of-IDX184-in-HCV-infected-patients.aspx